Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) EBITDA Margin (2021 - 2025)

Inmune Bio (INMB) has disclosed EBITDA Margin for 5 consecutive years, with 19548.0% as the latest value for Q1 2025.

  • Quarterly EBITDA Margin rose 5827343.0% to 19548.0% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 92190.0% through Dec 2025, up 20679571.0% year-over-year, with the annual reading at 92190.0% for FY2025, 20679571.0% up from the prior year.
  • EBITDA Margin hit 19548.0% in Q1 2025 for Inmune Bio, up from 77821.43% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4201.23% in Q1 2022 to a low of 113875.0% in Q1 2021.
  • Historically, EBITDA Margin has averaged 33253.56% across 5 years, with a median of 19548.0% in 2025.
  • Biggest five-year swings in EBITDA Margin: surged 10967377bps in 2022 and later crashed -6059774bps in 2024.
  • Year by year, EBITDA Margin stood at 5860.12% in 2021, then grew by 5bps to 5556.7% in 2022, then plummeted by -445bps to 30257.14% in 2023, then tumbled by -157bps to 77821.43% in 2024, then skyrocketed by 75bps to 19548.0% in 2025.
  • Business Quant data shows EBITDA Margin for INMB at 19548.0% in Q1 2025, 77821.43% in Q1 2024, and 30257.14% in Q4 2023.